Form 4: Amphastar Pharmaceuticals Executive Yakob Liawatidewi Reports Stock Transactions
SEC Form 4 Filing
Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.
Summary
- On November 6, 2024, Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, exercised stock options to acquire 5,214 shares of common stock at a price of $13.03 per share.
- Simultaneously, Liawatidewi sold 5,214 shares of common stock at $52.05 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 17, 2023.
- Following these transactions, Liawatidewi directly owns 74,938 shares and indirectly owns 2,459 shares through the Yakob and Sunmoon Trust.
- Liawatidewi also holds options for 10,962 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. The use of 10b5-1 trading plans allows insiders to sell shares over time while avoiding accusations of trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| July 25, 2013 | Date of the Yakob and Sunmoon Trust |
| November 17, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan |
| November 06, 2024 | Date of the reported transactions (option exercise and stock sale) |
| November 08, 2024 | Date of signature on the Form 4 filing |
| March 16, 2030 | Expiration date of the Employee Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.